These studies demonstrated that depletion of GAPDH sensitizes tumor cells to antimetabolite agents, however, this depletion did not alter the cell’s response to other chemotherapeutic drugs, such as doxorubicin and fludarabine [166,167]. The gene discussed is GAPDH; the disease is neoplasm.